Mariya I Meschaninova
Overview
Explore the profile of Mariya I Meschaninova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shatunova E, Rychkova A, Meschaninova M, Kabilov M, Tupikin A, Kurochkina Y, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596285
Chronic immunoinflammatory rheumatic diseases, such as axial spondyloarthritis (AxSpA), are accompanied by a dysregulation of bone remodeling. Among potential biomarkers of bone metabolism, the Wnt pathway antagonist, Dickkopf-1 (DKK-1), is...
2.
Bishani A, Meschaninova M, Zenkova M, Chernolovskaya E
Molecules
. 2024 Jul;
29(13).
PMID: 38999177
A short 19 bp dsRNA with 3'-trinucleotide overhangs acting as immunostimulating RNA (isRNA) demonstrated strong antiproliferative action against cancer cells, immunostimulatory activity through activation of cytokines and Type-I IFN secretion,...
3.
Chernikov I, Bachkova I, Senkova A, Meschaninova M, Savin I, Vlassov V, et al.
Cells
. 2024 May;
13(9.
PMID: 38727303
Small interfering RNA (siRNA) holds significant therapeutic potential by silencing target genes through RNA interference. Current clinical applications of siRNA have been primarily limited to liver diseases, while achievements in...
4.
Chernikov I, Ponomareva U, Meschaninova M, Bachkova I, Vlassov V, Zenkova M, et al.
Molecules
. 2024 Feb;
29(4).
PMID: 38398538
Cholesterol siRNA conjugates attract attention because they allow the delivery of siRNA into cells without the use of transfection agents. In this study, we compared the efficacy and duration of...
5.
Chernikov I, Ponomareva U, Meschaninova M, Bachkova I, Teterina A, Gladkikh D, et al.
Nucleic Acid Ther
. 2023 Nov;
33(6):361-373.
PMID: 37943612
Conjugation of small interfering RNA (siRNA) with lipophilic molecules is one of the most promising approaches for delivering siRNA . The rate of molecular weight-dependent siRNA renal clearance is critical...
6.
Kropacheva N, Golyshkin A, Vorobyeva M, Meschaninova M
Molecules
. 2023 Feb;
28(4).
PMID: 36838892
One of the key problems in the design of therapeutic and diagnostic oligonucleotides is the attachment of small-molecule ligands for targeted deliveries in such a manner that provides the controlled...
7.
Novopashina D, Dymova M, Davydova A, Meschaninova M, Malysheva D, Kuligina E, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613750
Among the great variety of anti-cancer therapeutic strategies, boron neutron capture therapy (BNCT) represents a unique approach that doubles the targeting accuracy due to the precise positioning of a neutron...
8.
Meschaninova M, Entelis N, Chernolovskaya E, Venyaminova A
Molecules
. 2021 Apr;
26(8).
PMID: 33917095
One of the ways to efficiently deliver various drugs, including therapeutic nucleic acids, into the cells is conjugating them with different transport ligands via labile or stable bonds. A convenient...
9.
Chernikov I, Gladkikh D, Karelina U, Meschaninova M, Venyaminova A, Vlassov V, et al.
Molecules
. 2020 Apr;
25(8).
PMID: 32325757
Cholesterol derivatives of nuclease-resistant, anti- small-interfering RNAs were designed to contain a 2'-OMe-modified 21-bp siRNA and a 63-bp TsiRNA in order to investigate their accumulation and silencing activity in vitro...
10.
Chernikov I, Meschaninova M, Chernolovskaya E
Methods Mol Biol
. 2020 Feb;
2115:57-77.
PMID: 32006394
RNA interference (RNAi) is a powerful tool for suppressing gene expression associated with various diseases that are not amenable to treatment with low molecular weight drugs. Despite significant progress in...